Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study

Authors:

Abstract
Multiple sclerosis (MS), a chronic autoimmune disease of the central nervous system, is clinically perceived by relapses and progressive loss of neurological function, primarily attributed to inflammatory attacks leading to demyelination, axonal loss, and gliosis culminating in long-term multifocal sclerotic plaques in the brain and spinal cord.1-3 Oral disease-modifying therapy (DMT) options such as teriflunomide,4,5 fingolimod,6 dimethyl fumarate,7,8 and siponimod9 have broadened disease management options in MS. Despite significant progress in MS therapy, there is still an unmet need for effective, safe, and convenient treatments that can be used early in the disease course.10-12 Given the number of alternative options of oral treatments, head-to-head comparative trials to inform choices are still lacking.13

This publication has 41 references indexed in Scilit: